Nicolas Graber

• Responsible to support European affiliates for the launch of a new depot formulation of an atypical neuroleptic. • Conduct launch readiness assessments • Close collaboration with global marketing team in Indianapolis on the marketing strategy and ensure European alignment to strategy • Responsible for the European role out of the global marketing campaign. • Involvement and driver of several global and European marketing projects. • Close collaboration with EU regulatory and manufacturing getting re

• Member of the Lilly Suisse Board (Geschäftsleitung) Heavy influence on all key decisions concerning the affiliate and close collaboration with other departments like Corporate Affairs and Medical to achieve affiliate goals. • Olanzapine sales plans were achieved in 2005 (37M CHF), SOM stabilized after significant loss the years before. Olanzapine turnaround major achievement. • Based on a heavy turnover in the past recreate, realign and remotivate the Neuroscience marketing and sales team (app. 25 team-me